PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute Long COVID with Respiratory Complications

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced results from a Phase 2 study of LYT-100-COV (deupirfenidone) in ...

Related Keywords

California ,United States ,Daphne Zohar ,Toby Maher ,Keck School Of Medicine The University ,Puretech Health ,Twitter ,Nasdaq ,Tech Health ,Chief Executive Officer ,Professor Clinical Medicine ,Interstitial Lung Disease ,Keck School ,Southern California ,Principal Investigator ,Safety Monitoring ,Wholly Owned ,Founded Entities ,Annual Report ,